During Thursday’s Current trade, Shares of Advaxis, Inc. (NASDAQ:ADXS), gain 6.37% to $14.52.
Advaxis, Inc. (ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, declared that it has designated Shelonitda S. Rose, M.D., as Vice President, Clinical Development. Dr. Rose brings to Advaxis more than 15 years of experience in medical oncology and hematology clinical research.
In her role as Vice President, Clinical Development, Dr. Rose will report to Advaxis’s Executive Vice President, Chief Medical Officer, David J. Mauro, MD, Ph.D., and will oversee clinical development programs for the Company’s Lm Technology™ platform. Advaxis has initiated three new clinical trials in 2015, counting a combination study involving ADXS-PSA and Merck’s PD-1 checkpoint inhibitor KEYTRUDA® (pembrolizumab). In addition, the Company anticipates to initiate six additional clinical trials by the end of year to evaluate its Lm Technology™ immunotherapy in cervical cancer, HPV-associated anal cancer and HER2 expressing solid tumors.
Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States.
Shares of PVH Corp (NYSE:PVH), inclined 5.21% to $117.25, during its current trading session.
SPEEDO USA, a division of PVH Corp. (PVH), declared that five-time Olympic medalist, holder of two individual world records and competitive swimming superstar Missy Franklin has joined Team Speedo, marking her first endorsement since becoming a professional swimmer in March 2015. As part of Team Speedo, Franklin will serve as a year-round brand ambassador, sharing her love of the water to inspire others, and will wear Speedo race suits when she represents the US at all major competitions globally.
PVH Corp. operates as an apparel company in the United States and internationally. It designs, markets, and retails men’s and women’s apparel and accessories, branded dress shirts, neckwear, sportswear, jeanswear, intimate apparel, swim products, handbags, footwear, golf apparel, fragrances, cosmetics, eyewear, hosiery, socks, jewelry, watches, outerwear, small leather goods, and home furnishings, in addition to other related products.
Halozyme Therapeutics, Inc. (NASDAQ:HALO), during its Thursday’s current trading session gained 3.32% to $18.04.
Halozyme Therapeutics, Inc. (HALO) declared the Pancreas Center at the University of California, San Francisco (UCSF) has initiated a clinical research study of Halozyme’s investigational new drug, PEGPH20 in pancreatic cancer patients who are candidates for potentially curative surgery. The trial will be conducted within the UCSF Helen Diller Family Comprehensive Cancer Center.
The Phase 2 study will investigate PEGPH20 in combination with gemcitabine and nab-paclitaxel (ABRAXANE) in patients with borderline resectable Pancreatic Ductal Adenocarcinoma (PDAC). The study will track the progress of up to 36 patients through chemotherapy and surgical treatment.
PEGPH20 (PEGylated recombinant human hyaluronidase) targets the degradation of hyaluronan (HA), a chain of natural sugars that can accumulate around cancer cells, inhibiting other therapies. By degrading HA, PEGPH20 may enhance the access of co-administered chemotherapeutic and immunotherapeutic agents.
Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter abnormal tissue structures for clinical benefit.
Finally, Fortinet Inc (NASDAQ:FTNT), gained 1.39%, to $43.13.
Fortinet® (FTNT) the global leader in high-performance cybersecurity solutions, declared the launch of its FortiGate-600D enterprise firewall, the industry’s most competitive 10GBps mid-range network security appliance accessible to protect mid-market and enterprise organizations from advanced cyber attacks.
The new FortiGate-600D delivers five-times better performance contrast to competitive solutions, and provides the best price/performance in the industry. The solution is designed to provide superior security and performance for two key use cases:
- Deployment as a Next Generation Firewall (NGFW) at the edge of the network, allowing multiple security applications to be deployed without causing a bottleneck in the network.
- Deployment as an Internal Segmentation Firewall (ISFW), enabling customers to securely separate data stores inside the internal network — where traffic can run 10 to 100 times faster than Internet traffic — without affecting throughput.
Fortinet, Inc. provides cyber security solutions for enterprises, service providers, and government organizations worldwide. The company offers FortiGate physical and virtual appliances products that provide various integrated security and networking functions to protect data, applications, and users from network- and content-level security threats; FortiManager product family to manage the system configuration and security functions of multiple FortiGate devices from a centralized console; and the FortiAnalyzer product family, which enables the collection, analysis, and archiving of content and log data generated by its products.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
